MY202993A - Dosage forms and methods for enantiomerically enriched or pure bupropion - Google Patents

Dosage forms and methods for enantiomerically enriched or pure bupropion

Info

Publication number
MY202993A
MY202993A MYPI2020004315A MYPI2020004315A MY202993A MY 202993 A MY202993 A MY 202993A MY PI2020004315 A MYPI2020004315 A MY PI2020004315A MY PI2020004315 A MYPI2020004315 A MY PI2020004315A MY 202993 A MY202993 A MY 202993A
Authority
MY
Malaysia
Prior art keywords
bupropion
dosage forms
enantiomerically enriched
methods
pure bupropion
Prior art date
Application number
MYPI2020004315A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of MY202993A publication Critical patent/MY202993A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2020004315A 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion MY202993A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (1)

Publication Number Publication Date
MY202993A true MY202993A (en) 2024-05-31

Family

ID=67688503

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020004315A MY202993A (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Country Status (19)

Country Link
EP (1) EP3755312A4 (enrdf_load_stackoverflow)
JP (3) JP2021513998A (enrdf_load_stackoverflow)
KR (3) KR20230075531A (enrdf_load_stackoverflow)
CN (1) CN112087999A (enrdf_load_stackoverflow)
AU (3) AU2019223187B2 (enrdf_load_stackoverflow)
BR (1) BR112020017179A2 (enrdf_load_stackoverflow)
CA (1) CA3092076A1 (enrdf_load_stackoverflow)
CL (1) CL2020002166A1 (enrdf_load_stackoverflow)
CR (1) CR20200415A (enrdf_load_stackoverflow)
EC (1) ECSP20060179A (enrdf_load_stackoverflow)
IL (2) IL313368A (enrdf_load_stackoverflow)
MA (1) MA51914A (enrdf_load_stackoverflow)
MX (2) MX2020008704A (enrdf_load_stackoverflow)
MY (1) MY202993A (enrdf_load_stackoverflow)
NI (1) NI202000056A (enrdf_load_stackoverflow)
NZ (1) NZ767378A (enrdf_load_stackoverflow)
PE (1) PE20211752A1 (enrdf_load_stackoverflow)
SG (1) SG11202008056SA (enrdf_load_stackoverflow)
WO (1) WO2019165379A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313368A (en) * 2018-02-23 2024-08-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
WO2021055124A1 (en) * 2019-09-20 2021-03-25 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2318960A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
DE60330909D1 (de) * 2003-08-08 2010-02-25 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
IL313368A (en) * 2018-02-23 2024-08-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion

Also Published As

Publication number Publication date
CA3092076A1 (en) 2019-08-29
KR20240091043A (ko) 2024-06-21
IL276871A (en) 2020-10-29
EP3755312A1 (en) 2020-12-30
BR112020017179A2 (pt) 2020-12-22
CR20200415A (es) 2021-02-03
ECSP20060179A (es) 2020-12-31
NZ767378A (en) 2024-03-22
MX2023009281A (es) 2023-08-17
JP2024075655A (ja) 2024-06-04
AU2022204521A1 (en) 2022-07-21
CL2020002166A1 (es) 2020-10-23
MA51914A (fr) 2020-12-30
SG11202008056SA (en) 2020-09-29
IL276871B1 (en) 2024-07-01
KR20230075531A (ko) 2023-05-31
JP2021513998A (ja) 2021-06-03
AU2019223187A1 (en) 2020-09-17
WO2019165379A1 (en) 2019-08-29
AU2022204521B2 (en) 2024-09-05
AU2024205858A1 (en) 2024-09-05
IL313368A (en) 2024-08-01
EP3755312A4 (en) 2022-03-16
JP2022153638A (ja) 2022-10-12
MX2020008704A (es) 2020-12-07
CN112087999A (zh) 2020-12-15
KR20210003091A (ko) 2021-01-11
AU2019223187B2 (en) 2022-07-28
NI202000056A (es) 2021-01-11
PE20211752A1 (es) 2021-09-06
IL276871B2 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
MY202993A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
SG10201907367QA (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX2018002906A (es) Metodos de tratamiento de trastornos del desarrollo con pipradrol.
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2023009631A (es) Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi.
NZ766360A (en) Compositions comprising 15-hepe and methods of using the same
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
MY198201A (en) A Combination Medicament Comprising Phenylephrine And Paracetamol
CR20220119A (es) Formas de dosificación para bupropión enantioméricamente enriquecido o puro
CR20200616A (es) Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión
HK40068404A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
HK40066587A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2018013324A (es) Métodos y composiciones para el tratamiento del síndrome de rett.
Collins Breathing difficulty and sedation: case report
MX2023013983A (es) Metodo de tratamiento del temblor esencial.
ZA202201669B (en) Intrathecal administration of levetiracetam
MY203919A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
Tomita Thrombocytopenia, neutropenia and proteinuria: case report
Wang Tachycardia: case report
UA99842U (ru) Способ проводниковой анестезии
Vourvahis Lersivirine/methadone
UA88668U (uk) Спосіб лікування ішемічної хвороби серця, поєднаної з метаболічним синдромом на фоні дефіциту вітаміну d